Our team conducted a review of all the biotech acquisitions of 2021 and distilled it down to the acquisitions of drug discovery-focused biotechs.
Navigate the 2021 M&A Series
- the top overall drug discovery M&A transactions by value (Part 1)
- the transactions with disclosed upfront payments (Part 2)
- the most valuable small molecule acquisitions (Part 3)
- the most valuable large molecule transactions (Part 4)
- the small molecules acquired in 2021 M&A: deep dive (Part 5)
- the large molecules acquired in 2021 M&As: deep dive (Part 6)
Here, we provide a comprehensive overview of the full series, including a PDF poster book; a complete list of the acquired lead molecules with disclosed structures that were acquired in 2021, with an accompanying deep-dive slide deck; a complete list of acquisitions of biotech companies focused on molecular drug discovery in 2021, with an accompanying deep-dive slide deck; and finally an interactive table of all the biotech acquisitions of 2021.
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.